Interferon Stimulated Gene Expression Is a Biomarker for Primary Mitochondrial Disease
Annals of Neurology · 2024
DOI: 10.1002/ana.27081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, 2024. Verfasst von Nandaki Keshavan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Unit, Great Ormond Street Hospital, London, UK. Hauptthemen laut MEDLINE: Interferons, Biomarkers, Mitochondrial Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Great Ormond Street Hospital Children's Charity, NIHR Great Ormond Street Hospital Biomedical Research Centre, Action Medical Research.
Abstract (Originalsprache)
Objective
Mitochondria are implicated in regulation of the innate immune response. We hypothesized that abnormalities in interferon signaling may contribute to pathophysiology in patients with primary mitochondrial disease (PMD).
Methods
Expression of interferon stimulated genes (ISGs) was measured by real‐time polymerase chain reaction (PCR) in whole blood samples from a cohort of patients with PMD.
Results
Upregulated ISG expression was observed in a high proportion (41/55, 75%) of patients with PMD on at least 1 occasion, most frequently IFI27 upregulation, seen in 50% of the samples. Some patients had extremely high IFI27 levels, similar to those seen in patients with primary interferonopathies. A statistically significant correlation was observed between elevated IFI27 gene expression and PMD, but not between IFI27 and secondary mitochondrial dysfunction, suggesting that ISG upregulation is a biomarker of PMD. In some patients with PMD, ISG abnormalities persisted on repeat measurement over several years, indicative of ongoing chronic inflammation. Subgroup analyses suggested common ISG signatures in patients with similar mitochondrial disease mechanisms and positive correlations with disease severity among patients with identical genetic diagnoses.
Interpretation
Dysregulated interferon signaling is frequently seen in patients with PMD suggesting that interferon dysregulation is a contributor to pathophysiology. This may indicate a role for repurposing of immunomodulatory therapies for the treatment of PMDs by targeting interferon signaling. ANN NEUROL 2024;96:1185–1200
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Metabolic Unit, Great Ormond Street Hospital, London, UK.
- Mitochondrial Research Group, UCL Great Ormond Street Institute of Child Health, London, UK.
- Department of Immunology, Camelia Botnar Laboratory, Great Ormond Street Hospital, London, UK.
ORCID-Profile: Nandaki Keshavan, Shamima Rahman
Förderung
- Great Ormond Street Hospital Children's Charity
- NIHR Great Ormond Street Hospital Biomedical Research Centre
- Action Medical Research
- Freya Foundation
- Lily Foundation
- Great Ormond Street Hospital Charity
Zitieren
APA
Keshavan, N., Mhaldien, L., Gilmour, K., & Rahman, S. (2024). Interferon Stimulated Gene Expression Is a Biomarker for Primary Mitochondrial Disease. Annals of Neurology. https://doi.org/10.1002/ana.27081
Vancouver
Keshavan N, Mhaldien L, Gilmour K, Rahman S. Interferon Stimulated Gene Expression Is a Biomarker for Primary Mitochondrial Disease. Annals of Neurology. 2024. doi:10.1002/ana.27081
BibTeX
@article{Keshavan2024,
author = {Keshavan, Nandaki and Mhaldien, Lana and Gilmour, Kimberly and Rahman, Shamima},
title = {Interferon Stimulated Gene Expression Is a Biomarker for Primary Mitochondrial Disease},
journal = {Annals of Neurology},
year = {2024},
doi = {10.1002/ana.27081}
}
EUVIMED